Erythropoietin and subarachnoid hemorrhage.
Grasso
Giovanni
G
Sfacteria
Alessandra
A
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D018696:Neuroprotective Agents; D011994:Recombinant Proteins; D004921:Erythropoietin